Evidence map›Paper›PMID 35621688›Full record

ArticleCurrent oncology (Toronto, Ont.)2022

Open Surgery including Lymphadenectomy without Adjuvant Therapy for Uterine-Confined Intermediate- and High-Risk Endometrioid Endometrial Carcinoma.

Isao Otsuka, Takuto Matsuura, Takahiro Mitani, Koji Otsuka, Yoshihisa Kanamoto

Open access · goldAbstract read
In one paragraph

Article in Current oncology (Toronto, Ont.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Isao OtsukaDepartment of Obstetrics and Gynecology, Kameda Medical Center, Kamogawa 296-8602, Chiba, Japan.ORCID 0000-0002-5136-3050
Takuto MatsuuraDepartment of Obstetrics and Gynecology, Kameda Medical Center, Kamogawa 296-8602, Chiba, Japan.
Takahiro MitaniDepartment of Obstetrics and Gynecology, Kameda Medical Center, Kamogawa 296-8602, Chiba, Japan.
Koji OtsukaDepartment of Obstetrics and Gynecology, Kameda Medical Center, Kamogawa 296-8602, Chiba, Japan.
Yoshihisa KanamotoDepartment of Obstetrics and Gynecology, Kameda Medical Center, Kamogawa 296-8602, Chiba, Japan.
Kameda Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Minimally invasive surgery may not be an appropriate surgical approach in intermediate- and high-risk endometrial carcinoma, even though adjuvant therapy is given. The objective of this study was to evaluate the results of open surgery including lymphadenectomy without adjuvant therapy in patients with uterine-confined intermediate- and high-risk endometrioid endometrial carcinoma. Two hundred fifty-six patients with uterine-confined endometrioid endometrial carcinoma were treated with open surgery, including pelvic with or without para-aortic lymphadenectomy. Of the 81 patients with uterine-confined intermediate- or high-risk disease, 77 were treated with systematic lymphadenectomy without adjuvant therapy. Seven patients developed recurrence, comprising 5.5% (3/55) and 18.2% (4/22) of the intermediate- and high-risk patients, respectively. The time to recurrence was 1-66 months. The sites of recurrence were the vaginal apex (

Indexed as

Endometrial NeoplasmsLymph Node ExcisionFemaleHumansLymphatic MetastasisNeoplasm StagingProspective StudiesRetrospective Studiesadjuvant therapyendometrioid endometrial carcinomahigh-riskintermediate-risklymphadenectomyopen surgeryrecurrence

Identifiers

PMID35621688
PMCPMC9139559
OpenAlexW4280507151

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.